ArticleFrontiers in pharmacology2023
Exploring the mechanism of aloe-emodin in the treatment of liver cancer through network pharmacology and cell experiments.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Phytochemistry, Bioavailability, and Molecular Mechanisms Underlying Multitarget Anticancer Activity ofNutrients · 2026Review
- Article
- Assessment of Anticancer Effects of Aloe vera on 3D Liver Tumor Spheroids in a Microfluidic Platform.Biotechnology and bioengineering · 2025Article
- Network toxicology reveals glyphosate mechanisms in kidney injury and cancer.Scientific reports · 2025Article
- Current status and trend of global research on the pharmacological effects of emodin family: bibliometric study and visual analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Bioinformatics prediction of function of T-cell exhaustion related genes in ischemic stroke.Scientific reports · 2025Article
- Prediction of potential targets of aloe-emodin in the treatment of hepatocellular carcinoma using network pharmacology combined with bioinformatics.Discover oncology · 2025Article
- Gamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy.World journal of gastrointestinal surgery · 2025Article
- Identification of novel therapeutic targets and effective anticancer agents for gallbladder cancer by integrating bioinformatics analysis and experimental validation.Frontiers in pharmacology · 2025Article
- Mechanism research on inhibition of gastric cancerOpen medicine (Warsaw, Poland) · 2025Article
- MOF-Mediated Aloe-Emodin Delivery Enhances Hepatocellular Carcinoma Immunotherapy via Pyroptosis and Immunosuppressant Synergy.International journal of nanomedicine · 2025Article
- To Explore the Active Components, Targets, and Potential Effects of Emodin in the Treatment of Colorectal Cancer Based on Network Pharmacology.PPAR research · 2025Article
- Aloe-emodin mediates the inhibitory effect of LncRNA D63785 on the PI3K/Akt/mTOR pathway in nasopharyngeal carcinoma.Frontiers in pharmacology · 2025Article
- Integrated Gut Microbiota, Metabolomics, and Network Pharmacology to Investigate the Anti-Alzheimer's Mechanism of Tripterygium Glycoside.Neuropsychiatric disease and treatment · 2025Article
- Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges.International journal of molecular sciences · 2024Review
- Article
- Review
- Research Progress on the Anti-Liver Cancer Mechanism and Toxicity of Rhubarb Anthraquinone.Drug design, development and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.